Skip to main content
. 2022 Nov 28;14(23):5868. doi: 10.3390/cancers14235868

Table 2.

Potential criteria for the choice of future first-line treatment.

Anti-Angiogenics-Based Anti-CTLA-4-Based
Bevacizumab-Based TKIs-Based
Strong criteria of choice Pre-existing untreated auto-immune disorder (psoriasis…) Severe vascular comorbidities
Significant Portal Hypertension
Criteria of choice subject to interpretation Better toxicity profile Non-severe vascular comorbidities
Equilibrated arterial hypertension
Low-risk auto-immune disorder (diabetes, thyroid disorder…)